ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

BIAFW bioAffinity Technologies Inc

0.39
0.00 (0.00%)
May 10 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 100
Bid Price 0.215
Ask Price 2,147.48
News -
Share Name Share Symbol Market Stock Type
bioAffinity Technologies Inc BIAFW NASDAQ Equity Warrant
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.39 16:00:00
Open Price Low Price High Price Close Price Previous Close
0.39 0.39
Trades Shares Traded Average Volume
1 100 -
Last Trade Type Quantity Price Currency
06:51:55 formt 100  0.3796 USD

bioAffinity Technologies Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
18.72M 9.50M - 2.53M -7.94M -0.84 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News bioAffinity Technologies

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BIAFW Message Board. Create One! See More Posts on BIAFW Message Board See More Message Board Posts

BIAFW Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.

Your Recent History

Delayed Upgrade Clock